Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita Inc. on March 16, 2005. The report discloses a material agreement entered into on December 6, 2004, to acquire all outstanding capital stock of Gambro Healthcare, Inc. from Gambro, Inc.
Key Financial Metrics
The filing specifies the transaction value for the acquisition of Gambro Healthcare at approximately $3.05 billion. The document does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for DaVita Inc. within the text of this report, noting instead that audited financial statements for Gambro Healthcare and unaudited pro forma consolidated information are attached as Exhibits 99.2 and 99.3.
Material Changes
The primary material change is the pending acquisition of Gambro Healthcare. The consummation of this transaction is contingent upon the satisfaction or waiver of several conditions, including the expiration of waiting periods under applicable antitrust regulations and the Company's ability to secure necessary financing.
Guidance, Outlook, and Risks
Management commentary is limited to the status of the acquisition agreement. Key risks and contingencies identified include regulatory approval under antitrust laws and the requirement to obtain financing to complete the deal. The filing incorporates by reference detailed financial analysis and pro forma information in the attached exhibits.
Investor Verification Checklist
- Verify the status of antitrust regulatory waiting periods and approvals.
- Confirm the Company's progress in securing the financing required for the $3.05 billion transaction.
- Review Exhibit 99.3 for unaudited pro forma condensed consolidated financial information to understand the combined entity's projected financial position.
- Examine Exhibit 99.2 for the audited combined financial statements of Gambro Healthcare.